Lower limb cellulitis is still a bedside diagnosis, not a laboratory one
A 71 year old woman arrives with 48 hours of pain, erythema, and swelling in the right lower leg. She is febrile at 38.3ºC but otherwise stable, alert, and able to walk independently. Her age, diabetes, venous stasis dermatitis, and unilateral leg findings place lower limb cellulitis high on the list, yet the first task is not to order a battery of tests. It is to decide whether the presentation is uncomplicated infection, a more severe systemic illness, or something that better fits another diagnosis altogether.
Cellulitis is an infection of the skin and subcutaneous tissue, and its burden is substantial. The Global Burden of Disease database estimated 54.8 million cases in 2019. Emergency department visits in the US remained stable between 2016 and 2023, but admission rates rose from 11.2% to 13.3%. In England and Wales, hospital admissions for skin and soft tissue infections increased by 145% between 1999 and 2020, from 183 to 449 per 100 000 population. Those numbers point to a condition that is common, expensive, and often managed in settings where clinical judgment must move quickly.
The core diagnostic principle is simple: uncomplicated cellulitis is usually a clinical diagnosis. Routine blood tests and cultures are not required in straightforward cases. Skin infection of this type often announces itself through a rapid evolution over hours to days, with warmth, tenderness, expanding erythema, and swelling. The pathophysiology is intuitive even when the bedside picture is messy: bacterial invasion of damaged skin and subcutaneous tissue ignites local inflammation, increases capillary leak, and produces the tense, painful edema that brings patients to urgent care.
Unilateral disease should keep cellulitis high on the differential
Lower limb cellulitis is almost always unilateral. Bilateral redness and swelling should immediately push the clinician to question the diagnosis and look for an alternative explanation. Venous stasis dermatitis, chronic edema, inflammatory dermatoses, and other mimics can resemble infection closely enough to tempt overtreatment, but cellulitis has a different tempo and pattern. A single inflamed leg, especially when symptoms have progressed over a day or two, deserves careful attention to that asymmetry.
Older adults carry higher risk, particularly those over 65. The case patient fits that profile, and her venous disease likely makes the skin barrier more vulnerable. Diabetes adds another layer of concern because impaired host defense and microvascular disease can blunt the usual clean edges of a skin infection and make deterioration harder to detect early. The practical consequence is not reflexive admission; it is more disciplined follow-up and a lower threshold to reconsider the diagnosis if the clinical course does not fit.
Oral therapy is enough for most uncomplicated cases
For uncomplicated cellulitis, oral antibiotics are first line. Penicillins or first generation cephalosporins given for five to seven days are the preferred treatment, and oral therapy is non-inferior to intravenous antibiotics in this setting. That matters at the bedside because the default assumption that “IV means stronger” does not hold here. When the patient is hemodynamically stable, able to take oral medication, and without signs of systemic illness beyond a mild fever, oral treatment avoids unnecessary admission and the complications that come with it.
The biological rationale is straightforward. If the infection is confined to the skin and subcutaneous tissue, drug delivery by mouth is usually sufficient to suppress bacterial growth and allow host immune defenses to reverse the inflammatory cascade. Escalating to intravenous therapy without a reason adds complexity without improving outcomes in the typical uncomplicated case.
A fever alone does not automatically convert a patient into a complicated case. Persistent tachycardia, tachypnoea, hypotension, systemic toxicity, or immunosuppression shift the concern toward more severe disease and justify a different level of care. In the stable patient, the better move is often prompt oral therapy and close review rather than immediate hospitalization.
Reassessment in 48 to 72 hours separates response from failure
The follow-up window is short. Reassess within 48 to 72 hours after starting antibiotics. Early review matters because cellulitis can look unimpressed during the first day of treatment, yet genuine progression should become obvious if therapy is failing, the diagnosis is wrong, or a deeper process is present. Improvement should be judged against the original extent of erythema, pain, swelling, and systemic features rather than by an arbitrary expectation of instant resolution.
This approach also helps prevent avoidable admissions. A rising hospital admission rate, despite stable emergency visits, suggests that clinicians are already feeling the strain of uncertainty at the front door. Clear diagnostic discipline, restraint with routine testing, and an oral-first treatment strategy offer a way to reduce that pressure without compromising care.
The unresolved challenge is not whether cellulitis exists. It is how often clinicians can distinguish it from mimics quickly enough to avoid unnecessary escalation while still identifying the small number of patients whose early fever or comorbidity marks the beginning of a more complicated course.